Status and phase
Conditions
Treatments
About
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
156 participants in 4 patient groups
Loading...
Central trial contact
Qingkai Zhou
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal